Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.
复制标题
DOI：
10.1093/cei/uxab020
复制
发表时间：
2022-07-22
影响因子：
4.6
通讯作者：
中科院分区：
文献类型：
--
作者：
尚未满足的卵巢癌有效治疗的临床需求尚未使用单克隆抗体（mAb）解决，这些抗体在很大程度上未能克服肿瘤相关的免疫抑制，限制癌症生长，并显着提高生存率。近年来，实验性mAb设计已经从仅针对卵巢肿瘤转移，而是寻求调节更广泛的肿瘤微环境（TME）。肿瘤相关巨噬细胞（TAM）可能是卵巢癌mAb的一个有吸引力的治疗靶点，因为它们的丰度高，与肿瘤细胞非常接近，并且它们积极参与促进几个促肿瘤过程。此外，几种抗体可结晶片段（Fc）受体的表达和TAM的广泛表型可塑性提供了使用mAb调节TAM极化以促进抗肿瘤表型的机会。在这篇综述中，我们讨论了TAMs在卵巢癌TME中的作用，以及通过mAb的合理设计来靶向这些细胞在肿瘤进展中的贡献的新兴策略。尚未满足的卵巢癌有效治疗的临床需求尚未使用单克隆抗体（mAb）解决。在这篇综述中，我们讨论了肿瘤相关巨噬细胞（TAMs）在卵巢癌中的作用，并考虑如何通过新型mAb疗法调节TAMs，为临床疗效提供独特的机会。
The unmet clinical need for effective treatments in ovarian cancer has yet to be addressed using monoclonal antibodies (mAbs), which have largely failed to overcome tumour-associated immunosuppression, restrict cancer growth, and significantly improve survival. In recent years, experimental mAb design has moved away from solely targeting ovarian tumours and instead sought to modulate the wider tumour microenvironment (TME). Tumour-associated macrophages (TAMs) may represent an attractive therapeutic target for mAbs in ovarian cancer due to their high abundance and close proximity to tumour cells and their active involvement in facilitating several pro-tumoural processes. Moreover, the expression of several antibody crystallisable fragment (Fc) receptors and broad phenotypic plasticity of TAMs provide opportunities to modulate TAM polarisation using mAbs to promote anti-tumoural phenotypes. In this review, we discuss the role of TAMs in ovarian cancer TME and the emerging strategies to target the contributions of these cells in tumour progression through the rationale design of mAbs. The unmet clinical need for effective treatments in ovarian cancer has yet to be addressed using monoclonal antibodies (mAbs). In this review we discuss the role of tumour-associated macrophages (TAMs) in ovarian cancer and consider how TAMs can be modulated by novel mAb therapies to provide unique opportunities for clinical efficacy.
登录
查看更多内容
影响因子：
4.7
作者：
Aghajanian C;Goff B;Nycum LR;Wang YV;Husain A;Blank SV
通讯作者：
Blank SV
影响因子：
11.5
作者：
Angevin, Eric;Tabernero, Josep;Kurzrock, Razelle
通讯作者：
Kurzrock, Razelle
影响因子：
20.3
作者：
Duluc, Dorothee;Delneste, Yves;Jeannin, Pascale
通讯作者：
Jeannin, Pascale
影响因子：
50.5
作者：
Delord, JP;Allal, C;Canal, P
通讯作者：
Canal, P
影响因子：
45.3
作者：
Bookman, MA;Darcy, KM;Horowitz, IR
通讯作者：
Horowitz, IR